Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients : a two-center propensity score matched study
BACKGROUND: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine in critically ill septic patient has been addressed in multiple studies; however, it's role in COVID-19 patients is still unclear. The aim of this study was to evaluate the use of thiamine as an adjunctive therapy on mortality in COVID-19 critically ill patients.
METHODS: This is a two-center, non-interventional, retrospective cohort study for critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. All patients aged 18 years or older admitted to ICUs between March 1, 2020, and December 31, 2020, with positive PCR COVID-19 were eligible for inclusion. We investigated thiamine use as an adjunctive therapy on the clinical outcomes in critically ill COVID-19 patients after propensity score matching.
RESULTS: A total of 738 critically ill patients with COVID-19 who had been admitted to ICUs were included in the study. Among 166 patients matched using the propensity score method, 83 had received thiamine as adjunctive therapy. There was significant association between thiamine use with in-hospital mortality (OR = 0.39; 95% CI 0.19-0.78; P value = 0.008) as well as the 30-day mortality (OR = 0.37; 95% CI 0.18-0.78; P value = 0.009). Moreover, patients who received thiamine as an adjunctive therapy were less likely to have thrombosis during ICU stay [OR (95% CI) 0.19 (0.04-0.88), P value = 0.03].
CONCLUSION: Thiamine use as adjunctive therapy may have potential survival benefits in critically ill patients with COVID-19. Additionally, it was associated with a lower incidence of thrombosis. Further interventional studies are required to confirm these findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Critical care (London, England) - 25(2021), 1 vom: 30. Juni, Seite 223 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al Sulaiman, Khalid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
30-day mortality |
|---|
| Anmerkungen: |
Date Completed 09.07.2021 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13054-021-03648-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327400536 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327400536 | ||
| 003 | DE-627 | ||
| 005 | 20231225200714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-021-03648-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327400536 | ||
| 035 | |a (NLM)34193235 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al Sulaiman, Khalid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients |b a two-center propensity score matched study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.07.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine in critically ill septic patient has been addressed in multiple studies; however, it's role in COVID-19 patients is still unclear. The aim of this study was to evaluate the use of thiamine as an adjunctive therapy on mortality in COVID-19 critically ill patients | ||
| 520 | |a METHODS: This is a two-center, non-interventional, retrospective cohort study for critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. All patients aged 18 years or older admitted to ICUs between March 1, 2020, and December 31, 2020, with positive PCR COVID-19 were eligible for inclusion. We investigated thiamine use as an adjunctive therapy on the clinical outcomes in critically ill COVID-19 patients after propensity score matching | ||
| 520 | |a RESULTS: A total of 738 critically ill patients with COVID-19 who had been admitted to ICUs were included in the study. Among 166 patients matched using the propensity score method, 83 had received thiamine as adjunctive therapy. There was significant association between thiamine use with in-hospital mortality (OR = 0.39; 95% CI 0.19-0.78; P value = 0.008) as well as the 30-day mortality (OR = 0.37; 95% CI 0.18-0.78; P value = 0.009). Moreover, patients who received thiamine as an adjunctive therapy were less likely to have thrombosis during ICU stay [OR (95% CI) 0.19 (0.04-0.88), P value = 0.03] | ||
| 520 | |a CONCLUSION: Thiamine use as adjunctive therapy may have potential survival benefits in critically ill patients with COVID-19. Additionally, it was associated with a lower incidence of thrombosis. Further interventional studies are required to confirm these findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a 30-day mortality | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Critically ill | |
| 650 | 4 | |a Intensive care units (ICUs) | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Thiamine | |
| 650 | 4 | |a Vitamin B1 | |
| 650 | 4 | |a Vitamins | |
| 650 | 7 | |a Thiamine |2 NLM | |
| 650 | 7 | |a X66NSO3N35 |2 NLM | |
| 700 | 1 | |a Aljuhani, Ohoud |e verfasserin |4 aut | |
| 700 | 1 | |a Al Dossari, Maram |e verfasserin |4 aut | |
| 700 | 1 | |a Alshahrani, Asma |e verfasserin |4 aut | |
| 700 | 1 | |a Alharbi, Aisha |e verfasserin |4 aut | |
| 700 | 1 | |a Algarni, Rahmah |e verfasserin |4 aut | |
| 700 | 1 | |a Al Jeraisy, Majed |e verfasserin |4 aut | |
| 700 | 1 | |a Al Harbi, Shmeylan |e verfasserin |4 aut | |
| 700 | 1 | |a Al Katheri, Abdulmalik |e verfasserin |4 aut | |
| 700 | 1 | |a Al Eidan, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Al Bekairy, Abdulkareem M |e verfasserin |4 aut | |
| 700 | 1 | |a Al Qahtani, Nouf |e verfasserin |4 aut | |
| 700 | 1 | |a Al Muqrin, Mashael |e verfasserin |4 aut | |
| 700 | 1 | |a Vishwakarma, Ramesh |e verfasserin |4 aut | |
| 700 | 1 | |a Al Ghamdi, Ghassan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care (London, England) |d 1997 |g 25(2021), 1 vom: 30. Juni, Seite 223 |w (DE-627)NLM097399787 |x 1466-609X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:1 |g day:30 |g month:06 |g pages:223 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13054-021-03648-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 1 |b 30 |c 06 |h 223 | ||